Unlock instant, AI-driven research and patent intelligence for your innovation.

An anti-human cd25 chimeric monoclonal antibody and its preparation method and application

A monoclonal antibody and variable technology, applied in the field of antibody preparation, anti-human CD25 chimeric monoclonal antibody and its preparation, can solve the problem of inability to regulate T cell proliferation and achieve the effect of promoting T cell proliferation

Active Publication Date: 2021-07-13
SUZHOU BRIGHT SCISTAR ANTIBODY BIOTECHNOLOGY CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The cytoplasmic region of the IL-2 receptor α chain is short, and the dimer form of IL-2Rβ and IL-2Rγ is a necessary structure for the IL-2 signaling pathway, but only the dimer form of IL-2Rβ and IL-2Rγ In the presence of IL-2, IL-2 cannot effectively regulate the proliferation of T cells through the IL-2 receptor complex signaling pathway, so IL-2 receptor α, that is, CD25, has the function of increasing the affinity between the receptor and IL-2, and is mainly expressed in CD4 + T cell membrane surface, involved in regulatory CD4 + T cells differentiate and proliferate at physiologically low levels of IL-2

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An anti-human cd25 chimeric monoclonal antibody and its preparation method and application
  • An anti-human cd25 chimeric monoclonal antibody and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 Obtaining of Hybridomas Producing CD25 Monoclonal Antibodies

[0053] (1) Immune mice

[0054] Mice were immunized with fusion protein or transgenic cells, immunized four times with an interval of 21 days each time, and the orbital blood titer of the mice was measured 7-10 days after the fourth immunization.

[0055] (2) Cell culture

[0056] 1. One day before fusion, take one BALB / c mouse aged 6-7 weeks and place it in 75% ethanol solution for 2 minutes.

[0057] 2. The mouse spleen was aseptically taken out, placed in a 200-mesh stainless steel screen, and ground to obtain a single cell suspension. Wash twice with 1640 basal medium (1400rpm, 5min) for later use. Use 15% FBS 1640 medium to adjust the cell concentration to 2×10 5 / ml, drop into 96-well culture plate, 100μL per well, 37℃, 5%CO 2 cultured in an incubator.

[0058] 3. Cultivate overnight, and observe under a low-power microscope the next day. And spread subcloned cells 150ul.

[0059] (3)...

Embodiment 2

[0073] Example 2 CD25 mouse / human chimeric antibody acquisition method

[0074] 1. Extract the cDNA of hybridoma cells: extract RNA from the hybridoma cell line, and use RT-PCR technology to reverse-transcribe the obtained RNA into cDNA; use specially designed upstream and downstream primers to PCR clone the hybridoma cells chain variable region (mVH) and light chain variable region (mVL);

[0075] 2. mVH and mVL were respectively connected to the cloning vector (pJET cloning vector), and the connection product was transformed into competent bacteria DH5a. Since the pJET vector carries the ampicillin (Amp+) resistance gene, the transformed bacteria can be coated on the Amp-resistant LB solid On the culture medium, cultivate overnight at 37 °;

[0076] 3. The bacteria to be plated grow scattered colonies, select colonies with clear edges and good growth, and further sequence and identify them;

[0077] 4. According to the sequencing results, the candidate heavy and light chai...

Embodiment 3

[0087] 1. Isolation and extraction of PBMC

[0088] Aseptically extract blood from the apheresis platelet leukocyte filter, hereinafter referred to as filter blood, and dilute it with PBS 1:20; take normal heparin anticoagulated peripheral blood from the same individual, hereinafter referred to as peripheral blood, and dilute it with PBS 1:2; The above-mentioned diluted filter blood and peripheral blood were separated by conventional Ficoll to obtain PBMC, washed 2 times with PBS, counted, and the cell density was adjusted to 1x106 / ml with RPMI-1640 containing 10% FBS. Cells and filter blood PBMC cells.

[0089] 2. CFSE-labeled cells

[0090] Wherein, the method for detecting human peripheral blood T cell expansion in vitro with CFSE labeling is to take an appropriate amount of isolated human peripheral blood mononuclear cells (PBMC) in an appropriate amount of CFSE working solution, mix gently, and then place in a 37°C water bath for 10 Min, after centrifugation, remove the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-human CD25 chimeric monoclonal antibody and a preparation method thereof, comprising the amino acid sequence encoding the variable region of the antibody, a preparation method, and antibody function identification. The present invention extracts heavy chain variable region (mVH) and light chain variable region (mVL) from hybridoma cells secreting anti-human CD25 monoclonal antibody, connects them with cloning vector (pJET cloning vector), and transforms competent bacteria DH5a According to the sequencing results, the candidate heavy and light chain variable region sequences are retained, and the heavy and light chain variable region sequences matching the expression vector are amplified again by PCR, and the PCR product is connected with the linear expression vector that has been pre-treated by double enzyme digestion. The ligation product was transformed into competent bacteria DH5a, and plasmid extraction was carried out after expanding culture. The eukaryotic expression cell line 293 was co-transfected with the expression vectors connected with the heavy chain and light chain variable region genes of the target monoclonal antibody. The supernatant harvested from the culture contained the target antibody. The monoclonal antibody expressed by flow cytometry combined well with PBMC, and the positive rate was over 95%. The CD25 mouse / human chimeric antibody was obtained.

Description

technical field [0001] The invention relates to a preparation method of an antibody, in particular to an anti-human CD25 chimeric monoclonal antibody and its preparation method and application, belonging to the field of biotechnology. Background technique [0002] CD25 is the α chain of the interleukin 2 (interleukin 2, IL-2) heterotrimeric receptor complex, which forms an IL-2 receptor complex with the IL-2 receptor β chain (CD122) and γ chain (CD132) . IL-2 is interleukin-2 (interleukin-2, IL-2), also known as T cell growth factor (T cell growth factor, TCRF). Activated CD4 + Cytokines produced by Th1 cells with a wide range of biological activities. It can promote the proliferation of Th0 and CTL, so it is an important factor in regulating immune response, and also participates in antibody response, hematopoiesis and tumor surveillance. [0003] The cytoplasmic region of the IL-2 receptor α chain is short, and the dimer form of IL-2Rβ and IL-2Rγ is a necessary structu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28A61K39/395A61P35/00
CPCA61K39/00C07K16/2866C07K2317/24C07K2317/56C07K2317/73
Inventor 张学光
Owner SUZHOU BRIGHT SCISTAR ANTIBODY BIOTECHNOLOGY CO LTD